Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Highly sensitive detection of ALK resistance mutations in plasma using droplet digital PCR

Fig. 1

Schematic outlining the protocol used to detect recurrent ALK mutations from plasma-derived cfDNA. Firstly, blood collection from patients with ALK-positive NSCLC was performed, cell-free plasma was extracted. The cfDNA was isolated in the purification process and quantified using Qubit. We used a ddPCR genotyping assay in conjunction with the QX200 Droplet Digital PCR System. The cfDNA was analyzed in two steps. In the first step, cfDNA was analyzed using screening probes. In the second step, cfDNA mutations detected in the screening phase were re-analyzed with mutation-specific probes

Back to article page